Hadjiev - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Hadjiev

Showing results (151-160 of 153) with videos related to

Pageof 16

Sort By:

You have reached the last page of results.This site can display upto 153 results.

Blood Cells, Molecules & Diseases|April 28, 2019

Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.

Blood Cells, Molecules & Diseases|April 23, 2018

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.

Khirurgiia|July 9, 2015

EPIDEMIOLOGICAL REGISTRY OF NEUROENDOCRINE TUMORS IN BULGARIA--A PILOT SURVEYR Stefanov, Ts Miteva-Katrandjieva, G Iskrov, et al.

Pageof 16

Search research articles

Showing results (151-160 of 153) with videos related to

Sort By:

Pageof 16

You have reached the last page of results.This site can display upto 153 results.

Blood Cells, Molecules & Diseases|April 28, 2019

Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.

Blood Cells, Molecules & Diseases|April 23, 2018

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.

Khirurgiia|July 9, 2015

EPIDEMIOLOGICAL REGISTRY OF NEUROENDOCRINE TUMORS IN BULGARIA--A PILOT SURVEYR Stefanov, Ts Miteva-Katrandjieva, G Iskrov, et al.

Pageof 16